MRNA therapy takes on blood cancer in early human trial
NCT ID NCT07332663
First seen Jan 12, 2026 · Last updated May 22, 2026 · Updated 18 times
Summary
This early-phase study tests a new mRNA drug (WGb-0301) for people with B-cell blood cancers that have come back or not responded to standard treatments. The drug uses lipid nanoparticles to deliver mRNA that targets CD19 on cancer cells. The main goals are to find a safe dose and see if the treatment shrinks tumors. Only 9 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.